Estrogen Receptor Expression in Cutaneous Melanoma

Driscoll, Marcia S.; Grant‐Kels, Jane M.

doi:10.1001/archdermatol.2008.539

Cited by 29 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][6][7][8][9][10] The growing focus on the loss of ERb expression as a common step in cancer initiation and progression 11 has led researchers to revisit the role of oestrogens and ERs in malignant melanoma (MM). [12][13][14][15][16][17] The exact role of ERb in melanocytes remains unknown, but this hormone receptor may play an important role in the pathophysiology of melanocytes, [14][15][16][17] also considering the survival advantage for women with MM compared with men. [18][19][20][21][22] ERa and ERb have been detected in nonmelanocytic human skin cells, [23][24][25][26] whereas little information exists in the literature concerning ER expression by melanocytes in normal and diseased skin.…”

Section: Discussionmentioning

confidence: 99%

Oestrogen receptor beta and melanoma: a comparative study

Giorgi¹,

Gori²,

Gandini

et al. 2013

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Oestrogen receptor beta and melanoma: a comparative study

Giorgi¹,

Gori²,

Gandini

et al. 2013

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Immunocytochemistry of estrogens receptor has been shown to predict response of breast cancer to endocrine therapy (6)(7). Previous studies (8)(9)(10)(11)(12) reported that some tumors other than breast cancer have hormone receptors e.g melanoma, carcinoid tumors, pancreatic, and renal cancers. It is unknown whether salivary gland cancers are hormone dependent or independent.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical expression of oestrogens and progesterone receptors in carcinoma ex pleomorphic adenoma- undifferentiated and adenocarcinoma types

Tarakji

Nassani²,

Sloan³

2010

Med Oral

View full text Add to dashboard Cite

Cancer of the salivary gland is one of the common cancers in the head and the neck regions. This type of cancer develops in the minor and the major salivary glands, and it sometimes metastasizes to other organs, particularly the lung. Morphologic mimicry and similarity in the expression of steroid hormone receptors between salivary gland tumors and breast tumors are well-known phenomena and are occasionally debated in the field of surgical pathology. The expression of sex hormone receptors in some tumors suggests a role for these receptors in tumor pathogenesis and therapy. Previous studies of the expression of estrogens and progesterone receptors in salivary gland tumors have reported conflicting results. Objective: Our study aimed to characterize alteration in the immunohistochemical expression of estrogens receptor and progesterone receptor in the tumor cells of carcinoma arising in pleomorphic adenoma. Study design: 27 cases of carcinoma arising in pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined. Results: The results showed that 27 (100 %) of 27 cases had negative nuclear staining for either estrogens or progesterone receptors. Conclusion: Our data suggest that carcinomas arising in pleomorphic adenoma were not dependent on endocrine function.

show abstract

“…Sex hormones are known to be associated with increase of melanocytes and melanin production in human skin (7) and may thus be implicated in melanoma genesis. Supporting this hypothesis, benign nevi and melanoma have been shown to express estrogen-binding receptors (7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 92%

Antiestrogen Therapy for Breast Cancer Modifies the Risk of Subsequent Cutaneous Melanoma

Huber

Schaffar

Neyroud-Caspar

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

Increased risk of secondary melanoma after breast cancer has been reported. Several lines of evidence suggest that elevated estrogen levels may be implicated in melanoma etiology. Accordingly, use of antiestrogens should be associated with decreased risk of melanoma. We compared melanoma incidence among a cohort of breast cancer patients with and without antiestrogen therapy, with data from the Geneva Cancer Registry. The cohort consisted of 7,360 women diagnosed with breast cancer between 1980 and 2005. About 54% of these patients received antiestrogens. All women were followed until December 2008. We compared cutaneous melanoma incidence rates among patients with and without antiestrogens with those expected in the general population by age and period standardized incidence ratios (SIR). A total of 34 women developed a melanoma during the follow-up period. Compared with the general population, the risk of melanoma was higher for patients who did not receive antiestrogens (SIR: 1.60, 95% CI: 1.08-2.12, P ¼ 0.02). On the contrary, the risk was close to 1 (SIR: 0.98, 95% CI: 0.40-1.56, P ¼ 0.57) for patients who received antiestrogen therapy. This study suggests that antiestrogen therapy modifies the risk of melanoma after breast cancer. Although our results are in agreement with the hypothesis that estrogens could play a role in melanoma occurrence, they need to be replicated in a larger study with data on potential confounders. Cancer Prev Res; 5(1); 82-88. Ó2012 AACR.

show abstract

Estrogen Receptor Expression in Cutaneous Melanoma

Cited by 29 publications

References 30 publications

Oestrogen receptor beta and melanoma: a comparative study

Oestrogen receptor beta and melanoma: a comparative study

Immunohistochemical expression of oestrogens and progesterone receptors in carcinoma ex pleomorphic adenoma- undifferentiated and adenocarcinoma types

Antiestrogen Therapy for Breast Cancer Modifies the Risk of Subsequent Cutaneous Melanoma

Contact Info

Product

Resources

About